Publications by authors named "Michael Gregor"

Claim this Profile
F
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Michael Gregor

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia von Tresckow, Michael Gregor

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stüssi, Michael Gregor

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch, Michael Gregor

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of trephine bone marrow biopsies in the era of measurable residual diseaseResults from the CLL10 trial of the German CLL Study Group (GCLLSG).
Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide, Michael Gregor

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia.
Yves Chalandon, Philippe Rousselot, Sylvie Chevret, Jean-Michel Cayuela, Rathana Kim, Michael Gregor

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow, Michael Gregor

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Moritz Fürstenau, Arnon P Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang, Michael Gregor

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
Martine E D Chamuleau, Frank Stenner, Dana A Chitu, Urban Novak, Monique C Minnema, Michael Gregor

Lancet Haematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Moritz Fürstenau, Yvonne J Thus, Sandra Robrecht, Clemens H M Mellink, Anne-Marie van der Kevie-Kersemaekers, Michael Gregor

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Michael Gregor

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Gabriela Forestieri, Lodovico Terzi di Bergamo, Marina Deodato, Anna Maria Frustaci, Riccardo Moia, Michael Gregor

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomical heterogeneity of residual disease in chronic lymphocytic leukemia treated with ibrutinib.
Adalgisa Condoluci, Lisa Milan, Gabriela Forestieri, Lodovico Terzi di Bergamo, Valeria Spina, Michael Gregor

Hematol Oncol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thymic tumours: a single center surgical experience and literature review on the current diagnosis and management of thymic malignancies.
Fabrizio Minervini, Laura Boschetti, Michael Gregor, Mariano Provencio, Virginia Calvo, Gregor J Kocher

Gland Surg· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.
Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Michael Gregor

Cancers (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial.
Bob Löwenberg, Thomas Pabst, Johan Maertens, Patrycja Gradowska, Bart J Biemond, Michael Gregor

Blood Adv· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 among fit patients with CLL treated with venetoclax-based combinations.
Moritz Fürstenau, Petra Langerbeins, Nisha De Silva, Anna Maria Fink, Sandra Robrecht, Michael Gregor

Leukemia· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.
Yair Herishanu, Adir Shaulov, Riva Fineman, Sandra Bašić-Kinda, Ariel Aviv, Michael Gregor

Am J Hematol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG).
Nadine Kutsch, Jasmin Bahlo, Sandra Robrecht, Jeremy Franklin, Can Zhang, Michael Gregor

Hemasphere· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Clemens-Martin Wendtner, Michael Gregor

Leuk Lymphoma· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013.
Annatina Schnegg-Kaufmann, Anita Feller, Helen Baldomero, Alicia Rovo, Markus G Manz, Michael Gregor

Cancer Epidemiol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability and Cardio-protective Effects During Cardiopulmonary Bypass.
David Freiermuth, Berend Mets, Daniel Bolliger, Oliver Reuthebuch, Thomas Doebele, Michael Gregor

J Cardiothorac Vasc Anesth· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine Biomarkers of Tubular Renal Cell Damage for the Prediction of Acute Kidney Injury After Cardiac Surgery-A Pilot Study.
Tanja Mayer, Daniel Bolliger, Markus Scholz, Oliver Reuthebuch, Michael Gregor

J Cardiothorac Vasc Anesth· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sevoflurane and Isoflurane-Pharmacokinetics, Hemodynamic Stability, and Cardioprotective Effects During Cardiopulmonary Bypass.
David Freiermuth, Berend Mets, Daniel Bolliger, Oliver Reuthebuch, Thomas Doebele, Michael Gregor

J Cardiothorac Vasc Anesth· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Barbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, Raymonde Busch, Gabor Kovacs, Michael Gregor

Lancet Oncol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis